Using epigenetic therapy to treat lung fibrosis
Targeting Lung Fibrosis Using Epigenetic Therapy
This study is looking at how a drug called tazemetostat might help improve lung health for people with pulmonary fibrosis by changing the activity of a specific enzyme, and it will use both human and animal cells to see how it works.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kentucky NIH-funded |
| Lab location | 1 site (Lexington, United States) |
| Project ID | NIH-10990721 on NIH RePORTER |
What this research studies
This research investigates how modifying the activity of a specific enzyme, EZH2, can potentially reverse or prevent the progression of pulmonary fibrosis, a disease characterized by the buildup of scar tissue in the lungs. The study will utilize both human and mouse cell cultures, as well as established animal models, to explore the effects of an FDA-approved drug, tazemetostat, on lung cells. By examining how this drug influences cellular behavior and signaling pathways, the research aims to identify new therapeutic strategies for patients suffering from this debilitating condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pulmonary fibrosis who may not have responded adequately to existing therapies.
Not a fit: Patients with early-stage pulmonary fibrosis or those whose condition is stable may not see significant benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments that not only extend life but also improve lung function and quality of life for patients with pulmonary fibrosis.
How similar studies have performed: Previous research has shown promise in targeting epigenetic mechanisms for various diseases, suggesting that this approach may yield beneficial results for pulmonary fibrosis as well.
Where this research is happening
Lexington, United States
- University of Kentucky — Lexington, United States (Active)
Researchers
- Principal investigator: Brainson, Christine Fillmore — University of Kentucky
- Study coordinator: Brainson, Christine Fillmore
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.